Chinese pharmaceutical innovation has achieved a historic breakthrough in Africa! On July 25, 2025, Jiangsu Aidea Pharmaceutical Group Co., Ltd. (Aidea Pharma) received new drug approval from the Zanzibar Food and Drugs Authority (ZFDA) for its self-developed anti-HIV drug Aitribond®️ (Ainuomiti Tablets). This not only marks Aidea Pharma’s first innovative drug successfully entering the global market but also represents the first approval of a China-developed anti-HIV new drug in Africa, setting a critical milestone for China’s pharmaceutical industry in addressing global public health challenges.

Addressing Africa’s Critical Needs: A China-Developed Solution Sets Sail

Africa bears the heaviest burden of the global HIV epidemic, hosting approximately 70% of the world's people living with HIV (PWH). The approval of Aitribond®️ (Ainuomiti Tablets) in Zanzibar (a constituent state of the United Republic of Tanzania) opens a direct pathway for China’s innovation to reach those most in need, delivering a new " China-Developed Solution" to improve treatment accessibility and outcomes across Africa.

Six Clinical Advantages: Building a Robust Defense Against HIV

Aitribond ®️(Ainuomiti Tablets) earned approval through its well-rounded clinical value:

Proven Efficacy with Safety Benefits: Robust evidence for effectiveness and superior safety profile.

Immune Reconstitution & Minimal Resistance: Supports immune recovery with low resistance risk and reduced incidence.

Enhanced Adherence & Broad Accessibility: Simplified regimen improves long-term compliance, while affordable pricing enables wide accessibility.

Empowering Global Expansion: Charting a "World Path" for Chinese Medicines

This approval is strategically significant for Aidea Pharma’s internationalization and long-term growth. It not only validates the company’s innovation capabilities but also marks a pivotal step into the global market—especially high-need emerging economies.

"The launch of Aitribond®️ (Ainuomiti Tablets) in Zanzibar brings to life our aspiration to ‘Develop Chinese Medicines, Serve the World,’" stated Dr. Heliang Fu, Chairman of Aidea Pharma. "This is just the beginning. We will accelerate registrations across more African countries and more Belt and Road Initiative countries, committed to delivering high-quality, affordable Chinese innovations to global PWH. Together, we will contribute China’s scientific strength to ending the HIV public health threat."